Corona Remedies Shines in Q3 FY26: Strong Growth and Strategic Expansion

Corona Remedies Limited, an India-focused branded pharmaceutical company, has reported a robust financial performance for the third quarter and nine months ended December 31, 2025. The company's consolidated revenue from operations for Q3 FY26 stood at INR 342.4 Crore, marking a healthy 15.0% year-on-year growth. For the nine-month period (9M FY26), revenue reached INR 1,050.1 Crore, reflecting an impressive 16.3% increase over the previous year. This strong topline performance was complemented by significant growth in profitability, with adjusted Profit After Tax (PAT) for 9M FY26 surging by 30.7% to INR 154.1 Crore, comfortably exceeding the company's guidance of 20% PAT growth.

The company's performance underscores its strategic focus on chronic and semi-chronic segments, which contribute approximately 70%-72% of its total revenue. This emphasis has enabled Corona Remedies to consistently outpace the Indian Pharmaceutical Market (IPM), demonstrating a 1.82x growth compared to the IPM's average. The growth is primarily driven by volume and new product introductions, highlighting the effectiveness of its brand-building approach and distribution network. The company's EBITDA for 9M FY26 grew by almost 25% to INR 231.4 Crore, with EBITDA margin improving by 140 basis points to 22.0%.

Financial Highlights: A Snapshot

Strategic Expansion and Product Pipeline

Corona Remedies is actively pursuing strategic initiatives to broaden its market reach and product portfolio. A significant achievement is the EAEU-GMP certification received by its Bhayla facility in January 2026. This accreditation enables the company to enter five key Eurasian markets, including Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan, unlocking a substantial market opportunity estimated at USD 25 billion. This move aligns with the company's long-term vision of establishing and strengthening international partnerships.

The company's inorganic growth strategy continues to yield results. Following the acquisition of seven brands from Bayer Zydus Pharma Ltd in July 2025, Corona Remedies is set to commence commercialization in Q4 FY26 with the launch of Noklot Plus, an antiplatelet and combination therapy. Additionally, 4-5 products for the infertility segment are slated for launch in Q1 or Q2 FY27, targeting 3,000 top IVF centers. The company is also preparing to launch a GLP-1 injectable, 'Wyntide,' around March 2026, coinciding with the patent expiry, and three biosimilars in Q4 FY26, including Denosumab and Recombinant FSH. These new introductions are expected to further bolster its position in chronic therapy areas.

Operational Efficiency and Future Outlook

The company's operational efficiency is reflected in its strong return ratios, with annualized Return on Capital Employed (ROCE) at 48.0% and Return on Equity (ROE) at 31.1% for 9M FY26. The cash flow generation remains robust, with an OCF to EBITDA conversion of 86.3%, enabling disciplined reinvestment for growth. Management emphasized its commitment to maintaining a net cash surplus position and funding growth through internal accruals.

Looking ahead, Corona Remedies aims to sustain its revenue growth in the mid-teen range and PAT growth in the high-teen range. The company plans to expand its workforce by 5%-7% year-on-year to support its growth trajectory and deepen pan-India penetration. While acknowledging that employee costs are currently higher due to recent expansions, management expects these costs to normalize as the leverage from the expanded sales force improves. The company is also planning for a new manufacturing plant in FY28-FY29 to support future capacity needs, demonstrating a proactive approach to long-term sustainable growth.

Segmental Contribution (FY25)

Corona Remedies Limited continues to demonstrate strategic clarity and disciplined execution, translating into sustained financial performance and a strong foundation for future expansion. The focus on core therapeutic segments, coupled with strategic acquisitions and international market entries, positions the company for continued outperformance and value creation for its stakeholders.